Tag: CDMO
Bioconjugation Technology Selection during Early-Stage Development – A Strategy to Streamline...
Abstract
Bioconjugate therapeutics comprise a fast-growing class of drugs with applications in various disease areas. In the past years, particularly antibody-drug conjugates (ADCs) have undergone...
A Fantastic Voyage: From Magic Bullet to Antibody-drug Conjugate
Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer (and potentially other diseases). However, unlike chemotherapy, ADCs are intended to directly target and kill tumor cells while, at the same time sparing normal, healthy cells.
Opportunities for ADC Development and Manufacturing
At the 2022 World ADC Conference in San Diego, Stewart Mitchell, Executive Vice President and site head of Sterling Pharma Solutions' Deeside, U.K. facility, presented a case study on the development and GMP manufacture at the site.
A New Horizon in ADC Technology: A Panel Discussion
Targeted therapies such as antibody-drug conjugates (ADC) have opened new ways in targeting diseases like cancer and hematological malignancies. High-potent active pharmaceutical ingredients, also...
MilliporeSigma: New Innovation and Capacity to Advance Next Generation Antibody-drug Conjugate...
With the approval of new antibody-drug conjugates (ADC), the global market size for ADCs, valued at USD 4.3 billion in 2020, is expected to...
How a CDMO can Support ADC Manufacturing
Over the last decades, outsourcing of pharmaceutical development and manufacturing, driven by a variety of factors, has resulted in the growth of Contract Development...
MabPlex awards CloudWorks4All with Enterprise Resource Planning (ERP) Contract
MabPlex USA, the North American subsidiary, China-based MabPlex (Yantai, Shandong Province, China) has contracted systems integrator CloudWorks4All, a leading life science and cloud ERP...
Lonza to Provide Customer-Dedicated Suites for Commercialization of Bioconjugates
Lonza, in a statement, confirmed signing a strategic collaboration for bioconjugation with a global biopharma company.
Under the terms of the agreement, Lonza will construct...
Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement
Piramal Pharma Solutions, a contract development and manufacturing organization (CDMO) and San Francisco-based biotech Bolt Bioterapeutics have signed a production agreement in which Piramal...
Trio Pharmaceuticals and Ajinomoto Ink Agreement to Develop First-in-class Dual Functionality...
Patients being treated for cancer may often benefit from a combination of systemic cancer chemotherapies. The rationale for the combination of multiple anti-cancer therapies...
